NCT06126640进行中（未招募）3 期
A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,615
- 试验地点
- 2
- 主要终点
- Invasive disease-free survival (IDFS)
研究概览
简要总结
This study aims to Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants with Residual Invasive Disease Following Neoadjuvant Therapy，This study will examine SHR-A1811versus trastuzumab emtansine (T-DM1) in patients with HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes after neoadjuvant therapy.The primary objective is to compare invasive disease-free survival (IDFS) between SHR-A1811 and T-DM1 treatment arms in this population. The key secondary objective of the study is to evaluate disease-free survival (DFS), overall survival (OS) and distant recurrence-free interval (DRFI).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •The age is 18-75 years old (including both ends), and female
- •HER2 positive invasive breast cancer Confirmed by pathological examination
- •Clinical Stage before Neoadjuvant Therapy was T1-4, N0-3, M0 (excluding T1N0).
- •Residual invasive cancer confirmed by pathological examination after radical surgery must meet one of the following two conditions:
- •If the clinical stage before neoadjuvant therapy is cT4N0-3M0 or cT1-3N2-3M0, there is residual invasive cancer in the primary breast lesion and/or ipsilateral axillary lymph nodes after surgery.
- •If the clinical stage before neoadjuvant therapy was cT1-3N0-1M0 (except T1N0), there was residual invasive cancer in the ipsilateral axillary lymph nodes after surgery.
- •Previous neoadjuvant therapy must meet all of the following conditions:
- •Neoadjuvant chemotherapy: At least 6 treatment cycles, including no less than 9 weeks of taxane-based chemotherapy (anthracycline-containing chemotherapy allowed).
- •Neoadjuvant anti-HER2 targeted therapy: No less than 9 weeks of targeted therapy including trastuzumab must be completed.
- •Have received radical surgery for breast cancer:
- •The interval from the completion of radical surgery to the first random medication should be at least 3 weeks and no more than 12 weeks.
- •Hormone receptor (HR) status was confirmed by postoperative pathologic examination. HR positive is defined as positive for the estrogen receptor (ER) or progesterone receptor (PR), and HR negative is defined as negative for both ER and PR.
- •The ECOG score is 0 or 1
- •Heart function is good
- •Agree to birth control
排除标准
- •Stage IV metastatic breast cancer
- •Evidence of recurrent breast cancer, including local recurrence, regional recurrence and distant metastasis .
- •In the past 5 years, patients suffered from other malignant tumors, excluding cured basal cell carcinoma of skin andcervical carcinoma in situ,.
- •Previously received systemic anti-HER2-ADC drug therapy, including but not limited to trastuzumab emtansine (T-DM1), Trastuzumab Deruxtecan (T-DXd), etc.
- •Previous dosage requirements for anthracycline exposure meet one of the following conditions:
- •Doxorubicin or anthracyclines with similar exposure equivalent > 240mg/m2;
- •Epirubicin or liposomal doxorubicin hydrochloride > 480mg/m
- •History of cardiovascular diseases with clinical significance, such as severe/unstable angina pectoris, symptomatic congestive heart failure (NYHA ≥ Ⅱ), supraventricular or ventricular arrhythmia with clinical significance and requiring treatment or intervention, and myocardial infarction within 6 months.
- •Subjects with known or suspected interstitial pneumonia.
- •Known hereditary or acquired bleeding and thrombosis tendency.
- •History of active hepatitis B, hepatitis C or liver cirrhosis.
- •There were other serious physical or mental diseases or abnormal laboratory examinations that may increase the risk of participating in the study.
研究组 & 干预措施
SHR-A1811
Experimental
干预措施: SHR-A1811 (Drug)
Trastuzumab Emtansine (T-DM1)
Active Comparator
干预措施: Trastuzumab Emtansine (Drug)
结局指标
主要结局
Invasive disease-free survival (IDFS)
时间窗: Randomization until the disease progressed, up to approximately 77 months postdose
次要结局
- Distant recurrence-free interval (DRFI)(Randomization until distant recurrence or death from any cause, up to approximately 101 months postdose.)
- Safety endpointPercentage of Adverse Events in Participants(Baseline up to approximately 101 months postdose)
- Overall survival(OS)(Randomization until death from any cause, up to approximately 101 months postdose.)
- Disease-free survival (DFS)(Randomization until the disease progressed, up to approximately 77 months postdose)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain MetastasesMetastatic Breast CancerNCT05769010Henan Cancer Hospital125
进行中（未招募）
3 期
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]Breast CancerNCT03523585Daiichi Sankyo608
招募中
2 期
A phase2 study of trastumab and TS-1 for HER2-positive advanced gastric cancerGastric CancerJPRN-UMIN000006115Shimane University Hospital20
已完成
2 期
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Non-Small Cell Lung CancerNCT04644237Daiichi Sankyo152
招募中
2 期
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerHER2-positive Breast CancerInvasive Carcinoma of the BreastNode Negative Breast CancerMicrometastasis Breast CancerHormone Receptor Positive Breast CancerBreast CancerNCT04569747Dana-Farber Cancer Institute375